reglab/statecodes huggingface dataset:
Texas Administrative Code › Title 25 - HEALTH SERVICES › Part 7 - TEXAS MEDICAL DISCLOSURE PANEL › Chapter 602 - PROCEDURE REQUIRING FULL DISCLOSURE OF SPECIFIC RISKS AND HAZARDS-LIST A › Section 602.1 - Anesthesia Treatments and Procedures

Current through Reg. 49, No. 28; July 12, 2024
(a) Epidural.
(1) Nerve damage.
(2) Persistent back pain.
(3) Headache.
(4) Bleeding/epidural hematoma.
(5) Infection.
(6) Medical necessity to convert to general
				anesthesia.
(7) Brain
				damage.
(8) Chronic pain.
Texas Administrative Code › Title 25 - HEALTH SERVICES › Part 7 - TEXAS MEDICAL DISCLOSURE PANEL › Chapter 602 - PROCEDURE REQUIRING FULL DISCLOSURE OF SPECIFIC RISKS AND HAZARDS-LIST A › Section 602.2 - Cardiovascular System Treatments and Procedures

Current through Reg. 49, No. 28; July 12, 2024
(a) Cardiac.
(1) Coronary artery bypass.
(A) Acute myocardial infarction (heart
				attack).
(B) Hemorrhage (severe
				bleeding).
(C) Kidney
				failure.
(D) Stroke.
(E) Sudden death.
(F) Infection of chest wall/chest
				cavity.
Texas Administrative Code › Title 25 - HEALTH SERVICES › Part 7 - TEXAS MEDICAL DISCLOSURE PANEL › Chapter 602 - PROCEDURE REQUIRING FULL DISCLOSURE OF SPECIFIC RISKS AND HAZARDS-LIST A › Section 602.3 - Digestive System Treatments and Procedures

Current through Reg. 49, No. 28; July 12, 2024
(a)
				Cholecystectomy with or without common bile duct exploration.
(1) Pancreatitis.
(2) Injury to the tube between the liver and
				the bowel.
(3) Retained stones in
				the tube between the liver and the bowel.
(4) Narrowing or obstruction of the tube
				between the liver and the bowel.
(5) Injury to the bowel and/or intestinal
				obstruction.
Texas Administrative Code › Title 25 - HEALTH SERVICES › Part 7 - TEXAS MEDICAL DISCLOSURE PANEL › Chapter 602 - PROCEDURE REQUIRING FULL DISCLOSURE OF SPECIFIC RISKS AND HAZARDS-LIST A › Section 602.4 - Ear Treatments and Procedures

Current through Reg. 49, No. 28; July 12, 2024
(a) Stapedectomy.
(1) Facial paralysis.
(2) Diminished or bad taste.
(3) Total or partial loss of hearing in the
				operated ear.
(4) Brief or
				long-standing dizziness.
(5)
				Eardrum hole requiring more surgery.
(6) Ringing in the ear.
Texas Administrative Code › Title 25 - HEALTH SERVICES › Part 7 - TEXAS MEDICAL DISCLOSURE PANEL › Chapter 602 - PROCEDURE REQUIRING FULL DISCLOSURE OF SPECIFIC RISKS AND HAZARDS-LIST A › Section 602.5 - Endocrine System Treatments and Procedures

Current through Reg. 49, No. 28; July 12, 2024
(a)
				Thyroidectomy.
(1) Acute airway obstruction
				requiring temporary tracheostomy.
(2) Injury to nerves resulting in hoarseness
				or impairment of speech.
(3) Injury
				to parathyroid glands resulting in low blood calcium levels that require
				extensive medication to avoid serious degenerative conditions, such as
				cataracts, brittle bones, muscle weakness and muscle irritability.
(4) Lifelong requirement of thyroid
				medication.
Texas Administrative Code › Title 25 - HEALTH SERVICES › Part 7 - TEXAS MEDICAL DISCLOSURE PANEL › Chapter 602 - PROCEDURE REQUIRING FULL DISCLOSURE OF SPECIFIC RISKS AND HAZARDS-LIST A › Section 602.6 - Eye Treatments and Procedures

Current through Reg. 49, No. 28; July 12, 2024
(a) Eye muscle
				surgery.
(1) Additional treatment and/or
				surgery.
(2) Double
				vision.
(3) Partial or total
				blindness.
Texas Administrative Code › Title 25 - HEALTH SERVICES › Part 7 - TEXAS MEDICAL DISCLOSURE PANEL › Chapter 602 - PROCEDURE REQUIRING FULL DISCLOSURE OF SPECIFIC RISKS AND HAZARDS-LIST A › Section 602.7 - Female Genital System Treatments and Procedures

Current through Reg. 49, No. 28; July 12, 2024
(a) Hysterectomy (abdominal and vaginal).
(1) Uncontrollable leakage of
				urine.
(2) Injury to
				bladder.
(3) Injury to the tube
				(ureter) between the kidney and the bladder.
(4) Injury to the bowel and/or intestinal
				obstruction.
(5) Need to covert to
				abdominal incision.
(6) If
				laparoscopic surgery is utilized, include the following risks:
(A) Damage during introduction of trocar to
				adjacent intra-abdominal structures and organs (e.g., bowel, bladder, blood
				vessels, or nerves) and potential need for additional surgery.
(B) Trocar site complications (e.g.,
				hematoma, bleeding, leakage of fluid, or hernia formation).
(C) Air embolus (bubble causing heart failure
				or stroke).
(D) Change during the
				procedure to an open procedure.
(E)
				If cancer is present, may increase the risk of the spread of cancer.
Texas Administrative Code › Title 25 - HEALTH SERVICES › Part 7 - TEXAS MEDICAL DISCLOSURE PANEL › Chapter 602 - PROCEDURE REQUIRING FULL DISCLOSURE OF SPECIFIC RISKS AND HAZARDS-LIST A › Section 602.8 - Hematic and Lymphatic System Treatments and Procedures

Current through Reg. 49, No. 28; July 12, 2024
(a) Transfusion of blood and blood
				components.
(1) Serious infection including
				but not limited to Hepatitis and HIV which can lead to organ damage and
				permanent impairment.
(2)
				Transfusion related injury resulting in impairment of lungs, heart, liver,
				kidneys, and immune system.
(3)
				Severe allergic reaction, potentially fatal.
Texas Administrative Code › Title 25 - HEALTH SERVICES › Part 7 - TEXAS MEDICAL DISCLOSURE PANEL › Chapter 602 - PROCEDURE REQUIRING FULL DISCLOSURE OF SPECIFIC RISKS AND HAZARDS-LIST A › Section 602.9 - Breast Surgery (non-cosmetic) Treatments and Procedures

Current through Reg. 49, No. 28; July 12, 2024
(a) Radical or modified radical mastectomy.
(1) Limitation of movement of shoulder and
				arm.
(2) Permanent swelling of the
				arm.
(3) Loss of the skin of the
				chest requiring skin graft.
(4)
				Recurrence of malignancy, if present.
(5) Decreased sensation or numbness of the
				inner aspect of the arm and chest wall.
Texas Administrative Code › Title 25 - HEALTH SERVICES › Part 7 - TEXAS MEDICAL DISCLOSURE PANEL › Chapter 602 - PROCEDURE REQUIRING FULL DISCLOSURE OF SPECIFIC RISKS AND HAZARDS-LIST A › Section 602.10 - Male Genital System Treatments and Procedures

Current through Reg. 49, No. 28; July 12, 2024
(a) Orchidopexy (reposition of testis(es)).
(1) Removal of testicle.
(2) Atrophy (shriveling) of the testicle with
				loss of function.
Texas Administrative Code › Title 25 - HEALTH SERVICES › Part 7 - TEXAS MEDICAL DISCLOSURE PANEL › Chapter 602 - PROCEDURE REQUIRING FULL DISCLOSURE OF SPECIFIC RISKS AND HAZARDS-LIST A › Section 602.11 - Maternity and Related Cases Treatments and Procedures

Current through Reg. 49, No. 28; July 12, 2024
(a) Delivery (vaginal).
(1) Injury to bladder and/or rectum,
				including a fistula (hole) between bladder and vagina and/or rectum and
				vagina.
(2) Hemorrhage (severe
				bleeding) possibly requiring blood administration and/or hysterectomy (removal
				of uterus) and/or artery ligation (tying off) to control.
(3) Sterility (inability to get
				pregnant).
(4) Brain damage, injury
				or even death occurring to the fetus before or during labor and/or vaginal
				delivery whether or not the cause is known.
Texas Administrative Code › Title 25 - HEALTH SERVICES › Part 7 - TEXAS MEDICAL DISCLOSURE PANEL › Chapter 602 - PROCEDURE REQUIRING FULL DISCLOSURE OF SPECIFIC RISKS AND HAZARDS-LIST A › Section 602.12 - Musculoskeletal System Treatments and Procedures

Current through Reg. 49, No. 28; July 12, 2024
(a) Arthroplasty of
				any joints with mechanical device.
(1)
				Impaired function such as stiffness, limp, or change in limb length.
(2) Blood vessel or nerve injury.
(3) Pain.
(4) Blood clot in limb or lung.
(5) Failure of bone to heal.
(6) Infection.
(7) Removal or replacement of any implanted
				device or material.
(8) Dislocation
				or loosening requiring additional surgery.
(9) If performed on a child age 12 or under,
				include the following additional risks: problems with appearance, use, or
				growth requiring additional surgery.
Texas Administrative Code › Title 25 - HEALTH SERVICES › Part 7 - TEXAS MEDICAL DISCLOSURE PANEL › Chapter 602 - PROCEDURE REQUIRING FULL DISCLOSURE OF SPECIFIC RISKS AND HAZARDS-LIST A › Section 602.13 - Nervous System Treatments and Procedures

Current through Reg. 49, No. 28; July 12, 2024
(a)
				Craniotomy, craniectomy or cranioplasty.
(1)
				Loss of brain function such as memory and/or ability to speak.
(2) Recurrence, continuation or worsening of
				the condition that required this operation (no improvement or symptoms made
				worse).
(3) Stroke (damage to brain
				resulting in loss of one or more functions).
(4) Loss of senses (blindness, double vision,
				deafness, smell, numbness, taste).
(5) Weakness, paralysis, loss of
				coordination.
(6) Cerebrospinal
				fluid leak with potential for severe headaches.
(7) Meningitis (infection of coverings of
				brain and spinal cord).
(8) Brain
				abscess.
(9) Persistent vegetative
				state (not able to communicate or interact with others).
(10) Hydrocephalus (abnormal fluid buildup
				causing pressure in the brain).
(11) Seizures (uncontrolled nerve
				activity).
(12) Need for permanent
				breathing tube and/or permanent feeding tube.
Texas Administrative Code › Title 25 - HEALTH SERVICES › Part 7 - TEXAS MEDICAL DISCLOSURE PANEL › Chapter 602 - PROCEDURE REQUIRING FULL DISCLOSURE OF SPECIFIC RISKS AND HAZARDS-LIST A › Section 602.14 - Radiology Treatments and Procedures

Current through Reg. 49, No. 28; July 12, 2024
(a)
				Splenoportography (needle injection of contrast media into the spleen).
(1) All associated risks as listed under
				§
										602.2(b)(2) of
				this chapter (relating to Cardiovascular System Treatments and
				Procedures).
(2) Injury to the
				spleen requiring blood transfusion and/or removal of the spleen.
Texas Administrative Code › Title 25 - HEALTH SERVICES › Part 7 - TEXAS MEDICAL DISCLOSURE PANEL › Chapter 602 - PROCEDURE REQUIRING FULL DISCLOSURE OF SPECIFIC RISKS AND HAZARDS-LIST A › Section 602.15 - Respiratory System Treatments and Procedures

Current through Reg. 49, No. 28; July 12, 2024
(a) Biopsy and/or
				excision (removal) of lesion of larynx, vocal cords, trachea.
(1) Loss or change of voice.
(2) Swallowing or breathing
				difficulties.
(3) Perforation
				(hole) or fistula (connection) in esophagus (tube from throat to
				stomach).
Texas Administrative Code › Title 25 - HEALTH SERVICES › Part 7 - TEXAS MEDICAL DISCLOSURE PANEL › Chapter 602 - PROCEDURE REQUIRING FULL DISCLOSURE OF SPECIFIC RISKS AND HAZARDS-LIST A › Section 602.16 - Urinary System Treatments and Procedures

Current through Reg. 49, No. 28; July 12, 2024
(a)
				Partial nephrectomy (removal of part of the kidney).
(1) Incomplete removal of stone(s) or tumor,
				if present.
(2) Blockage of
				urine.
(3) Leakage of urine at
				surgical site.
(4) Injury to or
				loss of the kidney.
(5) Damage to
				organs next to kidney.
Texas Administrative Code › Title 25 - HEALTH SERVICES › Part 7 - TEXAS MEDICAL DISCLOSURE PANEL › Chapter 602 - PROCEDURE REQUIRING FULL DISCLOSURE OF SPECIFIC RISKS AND HAZARDS-LIST A › Section 602.17 - Psychiatric Treatments and Procedures

Current through Reg. 49, No. 28; July 12, 2024
(a)
				Electroconvulsive therapy with modification by intravenous muscle relaxants and
				sedatives.
(1) Memory changes of events prior
				to, during, and immediately following the treatment.
(2) Fractures or dislocations of
				bones.
(3) Significant temporary
				confusion requiring special care.
Texas Administrative Code › Title 25 - HEALTH SERVICES › Part 7 - TEXAS MEDICAL DISCLOSURE PANEL › Chapter 602 - PROCEDURE REQUIRING FULL DISCLOSURE OF SPECIFIC RISKS AND HAZARDS-LIST A › Section 602.18 - Radiation Therapy Treatments and Procedures

Current through Reg. 49, No. 28; July 12, 2024
(a) A
				child is defined for the purpose of this section as an individual who is not
				physiologically mature as determined by the physician using the appropriate
				medical parameters.
(b) Head and
				neck.
(1) Early reactions.
(A) Reduced and sticky saliva, loss of taste
				and appetite, altered sense of smell, nausea.
(B) Sore throat, difficulty swallowing,
				weight loss, fatigue.
(C) Skin
				changes: redness, irritation, scaliness, blistering or ulceration, color
				change, thickening, hair loss.
(D)
				Hoarseness, cough, loss of voice, and swelling of airway.
(E) Blockage and crusting of nasal
				passages.
(F) Inflammation of ear
				canal, feeling of "stopped up" ear, hearing loss, dizziness.
(G) Dry and irritable eye(s).
(H) In children, these reactions are likely
				to be intensified by chemotherapy before, during or after radiation
				therapy.
(I) In children,
				depression of blood count leading to increased risk of infection and/or
				bleeding is more common.
Texas Administrative Code › Title 25 - HEALTH SERVICES › Part 7 - TEXAS MEDICAL DISCLOSURE PANEL › Chapter 602 - PROCEDURE REQUIRING FULL DISCLOSURE OF SPECIFIC RISKS AND HAZARDS-LIST A › Section 602.19 - Laparoscopic, Thoracoscopic and Robotic Surgery Treatments and Procedures

Current through Reg. 49, No. 28; July 12, 2024
The following shall be in addition to risks and hazards of
				  the same surgery when done as an open procedure.
(1) Damage during introduction of trocar to
				adjacent intra-abdominal structures (e.g., organs, blood vessels, or other
				vital tissues) and potential need for additional surgery.
(2) Trocar site complications (e.g.,
				hematoma/bleeding, leakage of fluid, or hernia formation).
(3) Air embolus (bubble causing heart failure
				or stroke).
(4) Postoperative
				pneumothorax (collapsed lung).
(5)
				Subcutaneous emphysema (air in between skin layers).
(6) Change during the procedure to an open
				procedure.
(7) If cancer is
				present, may increase the risk of the spread of cancer.
Texas Administrative Code › Title 25 - HEALTH SERVICES › Part 7 - TEXAS MEDICAL DISCLOSURE PANEL › Chapter 602 - PROCEDURE REQUIRING FULL DISCLOSURE OF SPECIFIC RISKS AND HAZARDS-LIST A › Section 602.20 - Pain Management Treatments and Procedures

Current through Reg. 49, No. 28; July 12, 2024
(a)
				Neuroaxial procedures (injections into or around spine).
(1) Failure to reduce pain or worsening of
				pain.
(2) Nerve damage including
				paralysis (inability to move).
(3)
				Epidural hematoma (bleeding in or around spinal canal).
(4) Infection.
(5) Seizure.
(6) Persistent leak of spinal fluid which may
				require surgery.
(7) Breathing
				and/or heart problems including cardiac arrest (heart stops beating).
(8) Loss of vision.
(9) Stroke.
Texas Administrative Code › Title 25 - HEALTH SERVICES › Part 7 - TEXAS MEDICAL DISCLOSURE PANEL › Chapter 602 - PROCEDURE REQUIRING FULL DISCLOSURE OF SPECIFIC RISKS AND HAZARDS-LIST A › Section 602.21 - Dental Surgery Treatments and Procedures

Current through Reg. 49, No. 28; July 12, 2024
(a)
				Oral surgery.
(1) Extraction (removing
				teeth).
(A) Dry socket (inflammation in the
				socket of a tooth).
(B) Permanent
				or temporary numbness or altered sensation.
(C) Sinus communication (opening from tooth
				socket into the sinus cavity).
(D)
				Fracture of alveolus and/or mandible (upper and/or lower jaw).
Texas Administrative Code › Title 25 - HEALTH SERVICES › Part 7 - TEXAS MEDICAL DISCLOSURE PANEL › Chapter 602 - PROCEDURE REQUIRING FULL DISCLOSURE OF SPECIFIC RISKS AND HAZARDS-LIST A › Section 602.22 - Plastic Surgery and Surgery of the Integumentary System Treatments and Procedures

Current through Reg. 49, No. 28; July 12, 2024
(a) Augmentation
				mammoplasty (breast enlargement with implant).
(1) Bleeding around implant.
(2) Sensory changes or loss of nipple
				sensitivity.
(3) Failure,
				deflation, or leaking of implant requiring replacement.
(4) Worsening or unsatisfactory appearance
				including asymmetry (unequal size or shape).
(5) Problems with or the inability to
				breastfeed.
(6) Capsular
				contracture (hardening of breast).
Texas Administrative Code › Title 25 - HEALTH SERVICES › Part 7 - TEXAS MEDICAL DISCLOSURE PANEL › Chapter 603 - PROCEDURES REQUIRING NO DISCLOSURE OF SPECIFIC RISKS AND HAZARDS-LIST B › Section 603.2 - Cardiovascular System Treatments and Procedures

Current through Reg. 49, No. 28; July 12, 2024
(a) Excision and
				ligation of varicose veins of the leg.
(b) Arterial line for monitoring
				purposes.
Texas Administrative Code › Title 25 - HEALTH SERVICES › Part 7 - TEXAS MEDICAL DISCLOSURE PANEL › Chapter 603 - PROCEDURES REQUIRING NO DISCLOSURE OF SPECIFIC RISKS AND HAZARDS-LIST B › Section 603.3 - Digestive System Treatments and Procedures

Current through Reg. 49, No. 28; July 12, 2024
(a)
				Appendectomy.
(b) Hemorrhoidectomy
				with fistulectomy or fissurectomy.
(c) Hemorrhoidectomy.
(d) Incision or excision of perirectal
				tissue.
(e) Local excision and
				destruction of lesion, anus and rectum.
(f) Operations for correction of cleft
				palate.
(g) Repair of inguinal or
				ventral hernia.
(h) Repair and
				plastic operations on anus and rectum.
(i) Colonoscopy.
(j) Tonsillectomy with
				adenoidectomy.
(k) Tonsillectomy
				without adenoidectomy.
Texas Administrative Code › Title 25 - HEALTH SERVICES › Part 7 - TEXAS MEDICAL DISCLOSURE PANEL › Chapter 603 - PROCEDURES REQUIRING NO DISCLOSURE OF SPECIFIC RISKS AND HAZARDS-LIST B › Section 603.4 - Ear Treatments and Procedures

Current through Reg. 49, No. 28; July 12, 2024
(a)
				Myringotomy.
(b) Reconstruction of
				auricle of ear for skin cancer.
(c)
				Tympanoplasty without mastoidectomy.
Texas Administrative Code › Title 25 - HEALTH SERVICES › Part 7 - TEXAS MEDICAL DISCLOSURE PANEL › Chapter 603 - PROCEDURES REQUIRING NO DISCLOSURE OF SPECIFIC RISKS AND HAZARDS-LIST B › Section 603.6 - Eye Treatments and Procedures

Current through Reg. 49, No. 28; July 12, 2024
(a) Administration
				of topical, parenteral (such as IV), or oral drugs or pharmaceuticals,
				including, but not limited to, fluorescein angiography, orbital injection or
				periocular injections.
(b) Removal
				of extraocular foreign bodies.
(c)
				Chalazion excision.
Texas Administrative Code › Title 25 - HEALTH SERVICES › Part 7 - TEXAS MEDICAL DISCLOSURE PANEL › Chapter 603 - PROCEDURES REQUIRING NO DISCLOSURE OF SPECIFIC RISKS AND HAZARDS-LIST B › Section 603.8 - Hematic and Lymphatic System Treatments and Procedures

Current through Reg. 49, No. 28; July 12, 2024
(a) Biopsy of lymph nodes.
(b) Other procedures. No other procedures are
				assigned at this time.
Texas Administrative Code › Title 25 - HEALTH SERVICES › Part 7 - TEXAS MEDICAL DISCLOSURE PANEL › Chapter 603 - PROCEDURES REQUIRING NO DISCLOSURE OF SPECIFIC RISKS AND HAZARDS-LIST B › Section 603.9 - Breast Surgery (non-cosmetic) Treatments and Procedures

Current through Reg. 49, No. 28; July 12, 2024
(a) Needle biopsy.
(b) Incision and drainage of skin
				lesion.
Texas Administrative Code › Title 25 - HEALTH SERVICES › Part 7 - TEXAS MEDICAL DISCLOSURE PANEL › Chapter 603 - PROCEDURES REQUIRING NO DISCLOSURE OF SPECIFIC RISKS AND HAZARDS-LIST B › Section 603.10 - Male Genital System Treatments and Procedures

Current through Reg. 49, No. 28; July 12, 2024
(a) Biopsy of testicle.
(b) Placement of testicular
				prosthesis.
(c) Hydrocelectomy
				(removal/drainage of cyst in scrotum).
(d) Cystoscopy.
Texas Administrative Code › Title 25 - HEALTH SERVICES › Part 7 - TEXAS MEDICAL DISCLOSURE PANEL › Chapter 603 - PROCEDURES REQUIRING NO DISCLOSURE OF SPECIFIC RISKS AND HAZARDS-LIST B › Section 603.11 - Maternity and Related Cases Treatments and Procedures

Current through Reg. 49, No. 28; July 12, 2024
Intrauterine Devices (IUD).
Texas Administrative Code › Title 25 - HEALTH SERVICES › Part 7 - TEXAS MEDICAL DISCLOSURE PANEL › Chapter 603 - PROCEDURES REQUIRING NO DISCLOSURE OF SPECIFIC RISKS AND HAZARDS-LIST B › Section 603.12 - Musculoskeletal System Treatments and Procedures

Current through Reg. 49, No. 28; July 12, 2024
(a) Arthrotomy,
				arthrocentesis, or joint injection (unless performed on a child age 12 or
				under, see §
									602.12(g) of this
				title (relating to Musculoskeletal System Treatments and
				Procedures)).
(b) Closed reduction
				without internal fixation (unless performed on a child age 12 or under, see
				§
									602.12(g) of this
				title).
(c) Wound debridement
				(unless performed on a child age 12 or under, see §
									602.12(g) of this
				title).
(d) Needle biopsy or
				aspiration, bone marrow (unless performed on a child age 12 or under, see
				§
									602.12(g) of this
				title).
(e) Partial excision of
				bone (unless performed on a child age 12 or under, see §
									602.12(g) of this
				title).
(f) Removal of external
				fixation device (unless performed on a child age 12 or under, see §
									602.12(g) of this
				title).
(g) Traction or fixation
				without manipulation for reduction (unless performed on a child age 12 or
				under, see §
									602.12(g) of this
				title).
Texas Administrative Code › Title 25 - HEALTH SERVICES › Part 7 - TEXAS MEDICAL DISCLOSURE PANEL › Chapter 603 - PROCEDURES REQUIRING NO DISCLOSURE OF SPECIFIC RISKS AND HAZARDS-LIST B › Section 603.13 - Nervous System Treatments and Procedures

Current through Reg. 49, No. 28; July 12, 2024
(a)
				Lumbar puncture.
(b) Closure of
				meningomyelocele.
(c)
				Ventriculostomy with or without air ventriculogram.
(d) Cisternal puncture
				(diagnostic).
(e) Stereotactic
				surgery for dystonia.
(f) Insertion
				of skeletal tongs.
(g) Intravenous
				cut-down.
(h) Cervical 1-2 puncture
				(diagnostic).
Texas Administrative Code › Title 25 - HEALTH SERVICES › Part 7 - TEXAS MEDICAL DISCLOSURE PANEL › Chapter 603 - PROCEDURES REQUIRING NO DISCLOSURE OF SPECIFIC RISKS AND HAZARDS-LIST B › Section 603.14 - Radiology Treatments and Procedures

Current through Reg. 49, No. 28; July 12, 2024
(a)
				Lymphangiography.
(b)
				Discography.
(c) Lumbar puncture
				with/without injection of medication.
(d) Nerve root injection, epidural injection,
				nerve blocks, and radiofrequency treatments for pain control.
(e) Venography (Venogram) with contrast media
				by peripheral IV.
(f)
				Cholangiography with contrast media through existing drain; T-tube
				cholangiography.
(g) Urography
				(IVP) with contrast media.
(h)
				Radionuclide scans and/or blood flow studies.
(i) Gastrointestinal (GI) tract radiography
				and fluoroscopy.
(j)
				Nasogastric/nasojejunal tube placement with fluoroscopy.
(k) Percutaneous
				gastrostomy/gastrojejunostomy.
(l)
				Fistula or sinus tract injection.
(m) Sialography.
(n) Dacryocystography, stenting.
(o) Cystography,
				cystourethrography.
(p) Retrograde
				and antegrade urography.
(q)
				Larynogography, bronchography.
(r)
				Hysterosalpingography.
(s) ERCP
				(Endoscopic retrograde cholangio pancreatography).
(t) Galactography.
(u) Skeletal radiography and/or fluoroscopy
				(skull, mastoids, sinuses and facial bones; spine, ribs, pelvis;
				extremities).
(v) Foreign body
				radiography and/or fluoroscopy and foreign body retrieval.
(w) Chest and abdomen radiography and
				fluoroscopy.
(x) Portable
				radiography/fluoroscopy.
(y)
				Pelvimetry, fetogram.
(z) Magnetic
				Resonance Imaging/Magnetic Resonance Angiography without and with
				contrast.
(aa) Computed tomography
				scan/computed tomography angiogram without and with contrast media.
(bb) Ultrasound and Doppler
				studies.
(cc) Laminography,
				polytomography.
(dd) Soft-tissue
				radiography including xeroradiography and xeromammography.
(ee) Arthrography, arthrocentesis,
				tenography.
(ff) Ureteral or
				urethral balloon dilatation/stent.
(gg) Percutaneous suprapubic
				cystostomy.
(hh) Cyst
				aspiration/drainage/sclerosis.
(ii)
				Percutaneous or transvascular biopsy.
(jj) Paracentesis.
(kk) Thoracentesis.
Texas Administrative Code › Title 25 - HEALTH SERVICES › Part 7 - TEXAS MEDICAL DISCLOSURE PANEL › Chapter 603 - PROCEDURES REQUIRING NO DISCLOSURE OF SPECIFIC RISKS AND HAZARDS-LIST B › Section 603.15 - Respiratory System Treatments and Procedures

Current through Reg. 49, No. 28; July 12, 2024
(a) Aspiration of
				bronchus.
(b) Reduction of nasal
				fracture.
Texas Administrative Code › Title 25 - HEALTH SERVICES › Part 7 - TEXAS MEDICAL DISCLOSURE PANEL › Chapter 603 - PROCEDURES REQUIRING NO DISCLOSURE OF SPECIFIC RISKS AND HAZARDS-LIST B › Section 603.16 - Urinary System Treatments and Procedures

Current through Reg. 49, No. 28; July 12, 2024
(a)
				Nephrotomy (placement of drainage tubes).
(b) Biopsy of prostrate, bladder or
				urethra.
(c) Cystolithotomy
				(surgical removal of stone(s) from the bladder).
(d) Cystolitholapaxy (cystoscopic crushing
				and removal of bladder stone(s)).
(e) Cystostomy (placement of tube into the
				bladder).
(f) Urethrotomy (incision
				of the urethra).
(g)
				Diverticulectomy of the bladder (removal of outpouching of the
				bladder).
(h) Diverticulectomy or
				diverticulotomy of the urethra (repair or drainage of outpouching of the
				urethra).
(i) Lithotripsy (sound
				wave removal of stones from kidney and ureter).
Texas Administrative Code › Title 25 - HEALTH SERVICES › Part 7 - TEXAS MEDICAL DISCLOSURE PANEL › Chapter 603 - PROCEDURES REQUIRING NO DISCLOSURE OF SPECIFIC RISKS AND HAZARDS-LIST B › Section 603.19 - Laparoscopic/Thoracoscopic Surgery (including robotic surgery) Treatments and Procedures

Current through Reg. 49, No. 28; July 12, 2024
No procedures assigned at this time.
Texas Administrative Code › Title 25 - HEALTH SERVICES › Part 7 - TEXAS MEDICAL DISCLOSURE PANEL › Chapter 603 - PROCEDURES REQUIRING NO DISCLOSURE OF SPECIFIC RISKS AND HAZARDS-LIST B › Section 603.20 - Pain Management Treatments and Procedures

Current through Reg. 49, No. 28; July 12, 2024
(a)
				Trigger point injection (injection into tendon or muscle).
(b) Scar injection.
Texas Administrative Code › Title 25 - HEALTH SERVICES › Part 7 - TEXAS MEDICAL DISCLOSURE PANEL › Chapter 603 - PROCEDURES REQUIRING NO DISCLOSURE OF SPECIFIC RISKS AND HAZARDS-LIST B › Section 603.21 - Plastic Surgery and Surgery of the Integumentary System Treatments and Procedures

Current through Reg. 49, No. 28; July 12, 2024
(a) Cutting and
				preparation of skin grafts or small pedicle flaps.
(b) Removal or treatment of local skin or
				subcutaneous lesion.
(c) Excision
				of pilonidal sinus or cyst.
(d)
				Suture of skin.
(e) Wide or radical
				excision of skin lesion with or without graft.
(f) Z plasty with or without
				excision.
(g) Biopsy of skin or
				mucus membrane.
(h) Debridement of
				ulceration of the skin.
Texas Administrative Code › Title 25 - HEALTH SERVICES › Part 7 - TEXAS MEDICAL DISCLOSURE PANEL › Chapter 604 - DISCLOSURE FORMS › Section 604.1 - Disclosure and Consent Form

Current through Reg. 49, No. 28; July 12, 2024
(a) The Texas
				Medical Disclosure Panel adopts the following form which shall be used by a
				physician or health care provider to inform a patient or person authorized to
				consent for the patient of the possible risks and hazards involved in the
				medical treatments and surgical procedures named in the form. Except for the
				procedures shown in subsection (b) of this section, the following form shall be
				used for the medical treatments and surgical procedures described in Chapter
				602 of this title (relating to Procedures Requiring Full Disclosure of Specific
				Risks and Hazards--List A). Providers shall have the form available in both
				English and Spanish language versions. Both versions are available from the
				Health and Human Services Commission.
(1)
				English form.
Attached
				  Graphic
(2)
				Spanish form.
Attached
				  Graphic
Texas Administrative Code › Title 25 - HEALTH SERVICES › Part 7 - TEXAS MEDICAL DISCLOSURE PANEL › Chapter 604 - DISCLOSURE FORMS › Section 604.2 - Disclosure and Consent Form for Radiation Therapy

Current through Reg. 49, No. 28; July 12, 2024
The Texas Medical Disclosure Panel adopts the following form
				  to be used by a physician or health care provider to inform a patient or person
				  authorized to consent for a patient of the possible risks and hazards involved
				  in the radiation therapy named in the form. This form is to be used in lieu of
				  the general disclosure and consent form adopted in §
									604.1(a) of this
				  chapter (relating to Disclosure and Consent Form) for disclosure and consent
				  relating to only radiation therapy procedures. If a surgical or anesthetic
				  procedure is required in combination with a radiation therapy procedure, the
				  general disclosure and consent form as adopted in §
									604.1(a) of this
				  chapter and the form adopted in this section shall be used. The general
				  disclosure and consent form shall be used for the surgical or anesthetic
				  procedure and the radiation therapy disclosure and consent form shall be used
				  for the radiation therapy procedure. Providers shall have the form available in
				  both English and Spanish language versions. Both versions are available from
				  the Health and Human Services Commission.
(1) English form.
Attached
				  Graphic
(2)
				Spanish form.
Attached
				  Graphic
Texas Administrative Code › Title 25 - HEALTH SERVICES › Part 7 - TEXAS MEDICAL DISCLOSURE PANEL › Chapter 604 - DISCLOSURE FORMS › Section 604.3 - Informed Consent for Electroconvulsive Therapy

Current through Reg. 49, No. 28; July 12, 2024
(a)
				Health and Safety Code (HSC) §578.003, relating to Consent to Therapy,
				requires the Texas Department of State Health Services (DSHS) to adopt a
				standard written consent form to be used when electroconvulsive therapy is
				considered. HSC §578.003 requires that the form include the minimum
				information which is also required by the Texas Medical Disclosure Panel
				(panel) for electroconvulsive therapy. HSC §578.003 states that use of the
				consent form prescribed by DSHS in the manner described by HSC §578.003
				creates a rebuttable presumption that the disclosure requirements of Texas
				Civil Practice and Remedies Code §
									74.102
				have been met.
(b) The panel
				recognizes that DSHS has adopted a written consent form for electroconvulsive
				therapy in §
									405.108 of this title (relating to
				Informed Consent to ECT).
(c) If
				the DSHS consent form is in compliance with HSC §578.003, and contains the
				minimum information required by the panel for electroconvulsive therapy,
				specifically the risks and hazards identified by the panel, a physician or
				health care provider using the DSHS consent form for electroconvulsive therapy
				is not required to use both the DSHS form and the panel's Disclosure and
				Consent - Medical Care and Surgical Procedures form to document consent for the
				electroconvulsive therapy. This section does not constitute approval of DSHS's
				current consent form or of DSHS's assessment of the risks and hazards
				associated with electroconvulsive therapy.
(d) If the physician or healthcare provider
				will be administering List A anesthesia or analgesia in conjunction with
				electroconvulsive therapy, the panel recommends utilization of the panel's
				Disclosure and Consent - Anesthesia and /or Perioperative Pain Management
				(Analgesia) form set out at §
									604.5(1) or (2)
				of this chapter (relating to Disclosure and Consent Form for Anesthesia and/or
				Perioperative Pain Management (Analgesia)) to document disclosure and consent
				for the anesthesia and analgesia. The panel's form includes the risks and
				hazards identified by the panel for List A anesthesia and analgesia.
Texas Administrative Code › Title 25 - HEALTH SERVICES › Part 7 - TEXAS MEDICAL DISCLOSURE PANEL › Chapter 604 - DISCLOSURE FORMS › Section 604.4 - Disclosure and Consent Form for Hysterectomy

Current through Reg. 49, No. 28; July 12, 2024
The Texas Medical Disclosure Panel adopts the following form
				  which shall be used to provide informed consent to a patient or person
				  authorized to consent for the patient of the possible risks and hazards
				  involved in the hysterectomy surgical procedure named in the form. This form is
				  to be used in lieu of the general disclosure and consent form adopted in §
									604.1(a) of this
				  chapter (relating to Disclosure and Consent Form) for disclosure and consent
				  relating to only hysterectomy procedures. Providers shall have the form
				  available in both English and Spanish language versions. Both versions are
				  available from the Health and Human Services Commission.
(1) English form.
Attached
				  Graphic
(2)
				Spanish form.
Attached
				  Graphic
Texas Administrative Code › Title 25 - HEALTH SERVICES › Part 7 - TEXAS MEDICAL DISCLOSURE PANEL › Chapter 604 - DISCLOSURE FORMS › Section 604.5 - Disclosure and Consent Form for Anesthesia and/or Perioperative Pain Management (Analgesia)

Current through Reg. 49, No. 28; July 12, 2024
The Texas Medical Disclosure Panel adopts the following form
				  which shall be used to provide informed consent to a patient or person
				  authorized to consent for the patient of the possible risks and hazards
				  involved in anesthesia and/or perioperative pain management (analgesia).
				  Providers shall have the form available in both English and Spanish language
				  versions. Both versions are available from the Health and Human Services
				  Commission.
(1) English form.
Attached
				  Graphic
(2)
				Spanish form.
Attached
				  Graphic
Texas Administrative Code › Title 25 - HEALTH SERVICES › Part 9 - TEXAS DIABETES COUNCIL › Chapter 651 - CONDUCT OF COUNCIL MEETINGS › Section 651.2 - Applicability of Texas Open Meetings Law

Current through Reg. 49, No. 28; July 12, 2024
The council in all its meetings is subject to the
				  requirements of the Texas Open Meetings Act, Texas Civil Statute
				  6252-17.
Texas Administrative Code › Title 25 - HEALTH SERVICES › Part 9 - TEXAS DIABETES COUNCIL › Chapter 651 - CONDUCT OF COUNCIL MEETINGS › Section 651.3 - Notice of Meetings

Current through Reg. 49, No. 28; July 12, 2024
(a) Written notice
				giving the date, time, place, and subject of each meeting shall be prepared as
				required by the Texas Open Meetings Law.
(b) A copy of the notice shall be sent to
				each council member at least seven days prior to the meeting except in
				emergency cases as determined by the chairperson.
(c) The meetings will be held at least
				quarterly and generally will be located in Austin, Texas.
Texas Administrative Code › Title 25 - HEALTH SERVICES › Part 9 - TEXAS DIABETES COUNCIL › Chapter 651 - CONDUCT OF COUNCIL MEETINGS › Section 651.4 - Transaction of Business

Current through Reg. 49, No. 28; July 12, 2024
(a) All meetings
				will be conducted according to Robert Rules of Order, except as provided
				otherwise in these rules.
(b) All
				council actions taken must be approved by a majority vote of the members
				present. The chairperson may vote on any item of business as any other council
				member; however, in the case of a tie vote, the chairperson's vote shall be the
				tie breaker.
Texas Administrative Code › Title 25 - HEALTH SERVICES › Part 9 - TEXAS DIABETES COUNCIL › Chapter 651 - CONDUCT OF COUNCIL MEETINGS › Section 651.5 - Public Participation

Current through Reg. 49, No. 28; July 12, 2024
Requests from members of the public to participate in council
				  meetings shall be submitted to the chairperson prior to the beginning of the
				  meeting. The chairperson has the discretion to allow or disallow participation.
				  If the chairperson allows participation, he/she determines the manner and time
				  limits of the participation.
Texas Administrative Code › Title 25 - HEALTH SERVICES › Part 11 - CANCER PREVENTION AND RESEARCH INSTITUTE OF TEXAS › Chapter 701 - POLICIES AND PROCEDURES › Section 701.1 - Intent

Current through Reg. 49, No. 28; July 12, 2024
The Institute shall:
(1) Create and expedite innovation in the
				area of cancer research and enhance the potential for medical or scientific
				breakthrough in the prevention of cancer and cures for cancer;
(2) Attract, create, or expand research
				capabilities of public or private institutions of higher education and other
				public or private entities that will promote a substantial increase in cancer
				research and in the creation of high-quality new jobs in Texas; and
(3) Develop and implement the Texas Cancer
				Plan.
Texas Administrative Code › Title 25 - HEALTH SERVICES › Part 11 - CANCER PREVENTION AND RESEARCH INSTITUTE OF TEXAS › Chapter 701 - POLICIES AND PROCEDURES › Section 701.5 - Oversight Committee Bylaws

Current through Reg. 49, No. 28; July 12, 2024
The Oversight Committee shall adopt Bylaws to govern the
				  conduct of its meetings and its management of the Institute, consistent with
				  applicable law.
(1) The Bylaws shall
				include:
(A) A process to elect a presiding
				officer, assistant presiding officer, and any other officer positions that may
				be created by the Oversight Committee and to set terms of service for such
				positions;
(B) A meeting schedule
				that permits a public meeting to be held no less than once each calendar
				quarter, with appropriate notice and opportunity for a formal public comment
				period;
(C) Duties and
				responsibilities for the presiding officer and assistant presiding officer, as
				well as other additional officer positions that may be created by the Oversight
				Committee;
(D) Responsibilities of
				the Oversight Committee and the Committee's officers that are distinguished
				from responsibilities of the Chief Executive Officer and Institute
				employees;
(E) A process for the
				Oversight Committee to review the financial practices of the Institute,
				including a review of the annual financial audit of the Institute's activities
				and the Comptroller of Public Accounts' report and evaluation of the
				Institute's annual financial audit;
(F) A prohibition against an interlocking
				directorate between the Oversight Committee and any foundation established to
				benefit the Institute;
(G) A
				process for hiring a Chief Executive Officer and evaluating the Chief Executive
				Officer's job performance; and
(H)
				A designation of grounds for removal from the Oversight Committee based on
				illness, absence, or ineligibility and provide process for removal.
Texas Administrative Code › Title 25 - HEALTH SERVICES › Part 11 - CANCER PREVENTION AND RESEARCH INSTITUTE OF TEXAS › Chapter 701 - POLICIES AND PROCEDURES › Section 701.7 - Compliance Program

Current through Reg. 49, No. 28; July 12, 2024
(a) Oversight
				Committee Members, Institute Employees, Scientific Research and Prevention
				Program Committee Members, Program Integration Committee Members, Grant
				Applicants, Grant Recipients, and contract service providers are expected to
				comply with applicable laws, rules, regulations, and policies in conduct of
				their official duties and responsibilities as well as professional standards of
				business and personal ethics.
(b)
				The Institute's Compliance Program shall ensure that agency operations conform
				to federal and state regulations, and that such operations are undertaken
				consistent with the Institute's administrative rules, policies, and procedures.
(1) The Compliance Program shall specifically
				address at least the following agency operations: Grant Review Process, Grant
				Award financial reporting and performance monitoring, Institute financial
				reporting, internal accounting controls, and auditing.
(2) The Compliance Program shall implement
				and oversee systems and activities to detect and report instances of conduct
				that do not conform to applicable law or policy, as well as the timely response
				to non-conforming conduct and to prevent future similar conduct.
(3) The Compliance Program shall implement
				and enforce the Code of Conduct and Ethics as well as the consistent
				enforcement of other compliance standards and procedures adopted by the
				Oversight Committee.
Texas Administrative Code › Title 25 - HEALTH SERVICES › Part 11 - CANCER PREVENTION AND RESEARCH INSTITUTE OF TEXAS › Chapter 701 - POLICIES AND PROCEDURES › Section 701.9 - Report and Investigation of Compliance Violations

Current through Reg. 49, No. 28; July 12, 2024
(a) The Chief Compliance Officer oversees the
				Institute's activities related to the report and investigation of suspected
				compliance violations, including fraud, waste, and abuse.
(b) To encourage good faith reporting of
				suspected noncompliance, the Institute shall establish a system to receive
				confidential reports of suspected instances or events that failed to comply
				with the Institute's applicable laws, rules and policies, including allegations
				of fraud, waste, and abuse. The Institute may use a telephonic and/or
				electronic mailbox system, such as an "ethics hotline" to preserve
				confidentiality of communications regarding suspected compliance violations and
				the anonymity of a person making a compliance report or participating in a
				compliance investigation.
(1) Information
				describing how to report a suspected compliance violation, including a
				designated telephone number and electronic mail address for confidentially
				reporting suspected compliance violations, shall be displayed on the
				Institute's Internet website and included in all Institute contracts and
				agreements.
(2) Information
				describing how to report a suspected compliance violation shall be included in
				the Institute's employee policies manual, and discussed internally with
				Institute Employees and included in ethics training sessions.
(3) Only good faith reports made to the
				designated telephone number or electronic mailbox shall be
				investigated.
Texas Administrative Code › Title 25 - HEALTH SERVICES › Part 11 - CANCER PREVENTION AND RESEARCH INSTITUTE OF TEXAS › Chapter 701 - POLICIES AND PROCEDURES › Section 701.11 - Texas Cancer Plan

Current through Reg. 49, No. 28; July 12, 2024
The Institute shall develop, implement, continually monitor,
				  and revise the Texas Cancer Plan as necessary.
(1) The intent of the Texas Cancer Plan is to
				reduce the cancer burden across the state and improve the lives of Texans by
				providing a coordinated, prioritized, and actionable framework that will help
				guide statewide efforts to fight the human and economic burden of cancer in
				Texas.
(2) Activities undertaken by
				the Institute to monitor the Texas Cancer Plan will be described in the Annual
				Public Report required by Texas Health and Safety Code §
									102.052.
(3) The Institute will periodically update
				the Texas Cancer Plan by issuing a revised version of the Texas Cancer Plan
				every seven (7) years, unless a different timeline for a revised version of the
				Texas Cancer Plan is approved by a simple majority of the Oversight
				Committee.
(4) The Institute may
				solicit input from public or private institutions, government organizations,
				non-profit organizations, other public entities, private companies, and
				individuals affected by cancer to assist the Institute in monitoring,
				implementing, and revising the Texas Cancer Plan.
(5) The most recent version of the Texas
				Cancer Plan shall be posted on the Institute's Internet website. A hard copy of
				the Texas Cancer Plan may be requested by contacting the Institute
				directly.
Texas Administrative Code › Title 25 - HEALTH SERVICES › Part 11 - CANCER PREVENTION AND RESEARCH INSTITUTE OF TEXAS › Chapter 701 - POLICIES AND PROCEDURES › Section 701.13 - Advisory Committees

Current through Reg. 49, No. 28; July 12, 2024
The Oversight Committee may rely upon Advisory Committees of
				  experts to advise the Oversight Committee on issues related to cancer and to
				  inform Institute policies and procedures.
(1) The University Advisory Committee shall
				advise the Oversight Committee and Review Councils regarding the role of higher
				education in Cancer Research. The committee's membership is composed of the
				members specified by §
									102.154,
				Texas Health and Safety Code.
(2)
				The Oversight Committee shall create an ad hoc Advisory Committee to address
				childhood cancers.
(3) The
				Oversight Committee may create additional ad hoc Advisory Committees to advise
				the Oversight Committee on issues related to cancer.
(4) The presiding officer of the Oversight
				Committee appoints experts, including practitioners and patient advocates, to
				serve as ad hoc Advisory Committee members, subject to approval by the
				Oversight Committee, for terms of service determined by the Oversight
				Committee.
(A) When used in this section, the
				term "patient advocates" is not intended to and does not have the meaning
				ascribed to the same term defined by §
										701.3 of
				this chapter (relating to Definitions). The term, when used herein, applies
				more generally to the broad category of individuals that advocate, either
				personally or professionally, on behalf of a group of individuals affected by
				cancer. A patient advocate serving on an ad hoc Advisory Committee does not
				undergo the selection process or receive science-based training required by
				Patient Advocates under Chapter 703, §
										703.5
				of this title (relating to Scientific Research and Prevention Programs
				Committees).
(B) An Institute
				Employee, Oversight Committee Member, or Scientific Research and Prevention
				Programs Committee Member may not be a member of any Advisory Committee of the
				Institute.
(C) Grant Applicants and
				Grant Recipients may be Advisory Committee members.
Texas Administrative Code › Title 25 - HEALTH SERVICES › Part 11 - CANCER PREVENTION AND RESEARCH INSTITUTE OF TEXAS › Chapter 701 - POLICIES AND PROCEDURES › Section 701.15 - Scientific Research and Prevention Programs Committee Honoraria Policy

Current through Reg. 49, No. 28; July 12, 2024
The Institute recruits high level, highly respected, well
				  established members of the Cancer Research, Product Development, or Cancer
				  Prevention communities for appointments to Scientific Research and Prevention
				  Programs Committees to conduct Peer Review of Grant Applications. The Institute
				  may pay an honorarium to a Scientific Research and Prevention Programs
				  Committee Member, pursuant to the Institute's honoraria policy.
(1) The honoraria policy shall be set by the
				Chief Executive Officer in consultation with the Oversight Committee and
				updated from time to time as necessary upon written notification to the
				Oversight Committee. Changes made to the honoraria policy must be supported by
				written justification.
(2)
				Honoraria rates paid by the Institute must be based upon the responsibilities,
				hours committed, and hourly rate commensurate with the expertise and
				professional background of the Scientific Research and Prevention Programs
				Committee Members.
(3) The
				honoraria policy may provide a comparison to honoraria and related compensation
				paid by other similar grant-making organizations to ensure that honoraria
				payment rates are reasonable and competitive for the value the Institute
				receives.
(4) Minimum documentation
				requirements for honoraria payments shall be set forth in the honoraria
				policy.
(5) The Institute's
				honoraria policy shall be publicly available.
Texas Administrative Code › Title 25 - HEALTH SERVICES › Part 11 - CANCER PREVENTION AND RESEARCH INSTITUTE OF TEXAS › Chapter 701 - POLICIES AND PROCEDURES › Section 701.17 - Scientific Research and Prevention Programs Committee Member Residency Policy

Current through Reg. 49, No. 28; July 12, 2024
(a) To minimize the
				potential for Conflicts of Interest in the Peer Review of Grant Applications,
				the Institute recruits individuals who live and work outside of the State to
				serve as Scientific Research and Prevention Programs Committee Members,
				including Patient Advocates, unless a special need justifies using one or more
				individuals living or working in Texas.
(b) If an individual who lives or works in
				Texas is appointed to serve as a Scientific Research and Prevention Programs
				Committee Member, an explanation of the special need must be provided at the
				time the Chief Executive Officer's appointment is approved by the Oversight
				Committee and recorded in the minutes of the Oversight Committee
				meeting.